Drug affinity complex raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-01-16. Anything still debated is marked as such rather than presented as settled.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
=== Side-effects === Although patients at high risk of bleeding were excluded from the phase III clinical study (PROWESS), 25% of patients treated with drotrecogin and 18% of those receiving placebo experienced at least one bleeding event (principally ecchymoses or GI bleeding) during the 28-day study period. During treatment, serious bleeding events (e.g., intracranial hemorrhage, any life-threatening bleeding event, any bleeding event requiring administration of at least 3 units of packed red blood cells daily for 2 consecutive days) occurred in 2.4% of patients treated with drotrecogin and in 1% of those receiving placebo. No significant differences between geriatric patients and younger patients regarding bleeding events in the drotrecogin group were found. No non-bleeding side-effects were observed. A second study, encompassing approximately 1700 adult patients, was completed in 2011 and showed a comparable side-effect profile.
The most important contribution to the science of controlled release include: (1) the development of polymers and copolymers of N-(2-hydroxypropyl)methacrylamide (HPMA) as drug carriers; (2) the introduction of enzymatically degradable derivatives of these polymers; (3) fundamental studies of the rates of enzymatic degradation of oligopeptide side-chains in polymers; (4) determination of the relationship between polymer structure and rates of pinocytic uptake of those polymers into cells; (5) design and preparation of polymers capable of specific intralysosomal release of chemically bound therapeutic agents; (6) fundamental studies of tissue localization of polymeric carriers bearing ligands for receptors expressed on the surfaces of specific target cells. Three HPMA copolymer - anticancer drug conjugates were in Phase I/II clinical trials.
Likewise, the saturated zone of a soil frequently has a higher radon content than the unsaturated zone because of diffusional losses to the atmosphere. In 1971, Apollo 15 passed 110 km (68 mi) above the Aristarchus plateau on the Moon, and detected a significant rise in alpha particles thought to be caused by the decay of 222Rn. The presence of 222Rn has been inferred later from data obtained from the Lunar Prospector alpha particle spectrometer. Radon is found in some petroleum. Because radon has a similar pressure and temperature curve to propane, and oil refineries separate petrochemicals based on their boiling points, the piping carrying freshly separated propane in oil refineries can become contaminated because of decaying radon and its products. Residues from the petroleum and natural gas industry often contain radium and its daughters. The sulfate scale from an oil well can be radium rich, while the water, oil, and gas from a well often contains radon. Radon decays to form solid radioisotopes that form coatings on the inside of pipework.
Sources: en.wikipedia.org
Moderate pain, which improves on elevation (unlike arterial ulcers which worsen with elevation) Irregular, sloping edges Associated oedema, due to increased hydrostatic pressure, which contributes to 'atrophie blanche' 'Atrophie blanche', localised loss of skin pigmentation due to death of erythrocytes and scarring Lipodermatosclerosis, a hardening of the skin which can lead to an "inverted champagne bottle" appearance to the leg Associated superficial varicose veins or "ankle flare", a collection of small, dark, engorged superficial veins
=== Social groups === China Agricultural Means of Production Association China ASEAN Agricultural Materials Association China Cotton Association China Fruit Marketing Association China Tea Circulation Association China Edible Fungi Association China Renewable Resources Recycling and Utilization Association China Society of Supply and Marketing Cooperative Economics China Cotton and Hemp Circulation Economy Research Association Northeast Information Association
== V == Vanilla – the Totonac are believed to have been the first to extract vanilla from the pods of vanilla orchids and use it as a flavor enhancer. Vulcanization – the Olmec people of Veracruz, Mexico treated the sap from rubber trees with chemicals and shaped the resulting rubber into a myriad of products such as balls, sandals, balloons, rubber syringes, etc. centuries before Charles Goodyear re-invented the process during the 19th century.
Sources: en.wikipedia.org
=== Topical === The topical form of eflornithine is sold under the brand name Vaniqa. The most frequently reported side effect is acne (7–14%). Other side effects commonly (> 1%) reported are skin problems, such as skin reactions from in-growing hair, hair loss, burning, stinging or tingling sensations, dry skin, itching, redness or rash.
The Sanders campaign was bolstered by a wave of optimistic volunteers as well as a series of endorsements from university professors, social welfare agencies, and the police union. The result shocked the local political establishment. Sanders formed a coalition of independents and the Citizens Party. On December 3, 1982, he announced that he would seek reelection. On January 22, 1983, the Citizens Party voted unanimously to endorse Sanders, although Sanders ran as an independent. He was reelected, defeating Judy Stephany and James Gilson. Sanders initially considered not seeking a third term, but announced on December 5, 1984, that he would run. He formally launched his campaign on December 7 and was reelected. On December 1, 1986, Sanders, who had finished third in the 1986 Vermont gubernatorial election, announced that he would seek reelection to a fourth term as mayor of Burlington, despite close associates saying that he was tired of being mayor. Sanders defeated Democratic nominee Paul Lafayette in the election. He said he would not seek another mayoral term after the 1987 election: "eight years is enough and I think it is time for new leadership, which does exist within the coalition, to come up". Sanders did not run for a fifth term as mayor. He went on to lecture in political science at Harvard Kennedy School that year and at Hamilton College in 1991.
=== Single chain protein-polymer hybrids === Attaching a single polymer chain to a specific site away from the active center of the protein has less impact on protein activity compared with random attachments. In practice, attaching a single polymer chain can be used to adjust chemical properties of the therapeutic protein. For example, conjugation of a single chain of the hydrophilic polyethylene glycol (PEG) can increase the hydrodynamic radius of the protein conjugate by 5-10 fold. Attachment to PEG was mainly achieved by covalent conjugation via the grafting to strategy, targeting chemo-selective anchor groups. Other polymers, such as oligosaccharides and polypeptides, offer different properties to the enzymes attached to them.
== Insulin dysregulation == Insulin dysregulation is commonly seen in horses with PPID or equine metabolic syndrome. It is of interest primarily because of its link to laminitis. Horses with ID will have an increased insulin response after they are given oral sugars, which will cause a subsequent rise in blood insulin levels, or hyperinsulinemia. Hyperinsulinemia results in decreased tissue sensitivity to insulin, or insulin resistance especially by the skeletal muscle, liver and adipose tissue. Tissue insulin resistance causes increased insulin secretion, which perpetuates the cycle. The trigger to insulin resistance is not fully understood. Genetics is likely to have some impact on the risk of postprandial hyperinsulinemia. Obesity, pregnancy, PPID, and inflammatory states may contribute to tissue insulin resistance. PPID is thought to result in increased insulin secretion due to higher levels of CLIP produced by melanotrophs, and to cause insulin resistance secondary to hyperadrenocorticism.
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.